Protherics PLC, the biopharmaceutical company focused on critical care and oncology (the “Company”), announces the grant of 14,384 options over 2p ordinary shares in the Company (“Ordinary Shares”), on 11 January 2006, to James C Christie, Operations Director, under the terms of the Protherics PLC 1998 Savings-Related Share Option Scheme. The options are exercisable at a price of 65 pence per Ordinary Share between 1 February 2009 and 31 July 2009.
